Everest Medicines Limited provided earning guidance for the year ended 31 December 2023. The board of directors of the Company informed the shareholders and potential investors of the Company that, based on the preliminary review of the unaudited management accounts of the Group for the year ended 31 December 2023, the Group is expected to record a total revenue ranging between approximately RMB 124 million and approximately RMB 126 million for the year ended 31 December 2023, as compared to a total revenue of approximately RMB 12.8 million for the year ended 31 December 2022. The substantial increase in total revenue of the Group for the year ended 31 December 2023 was mainly due to (i) the approval of New Drug Application of Xerava (eravacycline) by National Medical Products Administration (NMPA) of China for the treatment of complicated intra-abdominal infections (cIAI) in adult patients in China in March 2023, and its successful launch in China in July 2023; as well as (ii) the approval of Nefecon in Macau in October 2023 and its successful launch in December 2023.